Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039104 · ClinicalTrials.gov registry record · Phase 2
Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00039104: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00039104 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00039104, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. BMS-275291 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Combining zoledronate with BMS-275291 may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG zoledronic acid
- DRUG rebimastat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2002-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039104
The ClinicalTrials.gov registry entry for NCT00039104 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00039104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039104 about?
NCT00039104 is a clinical study titled "Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer". Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. BMS-275291 may stop the growth of tumor c...
What is the current status of trial NCT00039104?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2002-04.
What interventions are being tested in trial NCT00039104?
The interventions under investigation include: laboratory biomarker analysis (OTHER), zoledronic acid (DRUG), rebimastat (DRUG).
Who is sponsoring clinical trial NCT00039104?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.